How to access Repatha from Kuwait, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Kuwaiti patient with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolaemia (HeFH) who is not at LDL-C goal on maximally tolerated statin therapy may receive a prescription for Repatha (evolocumab) from their treating cardiologist or lipidologist. Repatha is FDA-approved for LDL-C lowering and developed by Amgen. Repatha is registered in parts of Kuwait supply chain, but formulary coverage is uneven across institutions and specific presentations can be out of stock, this guide addresses access when your hospital formulary does not reliably provide Repatha.
This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Repatha is a fully human monoclonal antibody against PCSK9, administered subcutaneously every two weeks (140 mg) or monthly (420 mg) via auto-injector or pre-filled syringe. Eligibility anchors to LDL-C history above goal despite maximally tolerated statin therapy (with or without ezetimibe), documented ASCVD or HeFH, and patient capacity for self-administration. Your cardiologist sets the lipid follow-up cadence and injection-technique training plan.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Repatha legally importable into Kuwait?
Yes, via the Kuwait Ministry of Health (KMOH) named-patient / special-access import framework when Repatha is not on your specific hospital formulary, when the specific presentation/dose is not locally stocked, or when there is a supply gap at your institution.
The mechanism permits a KSA-licensed physician to import a medicine not routinely available at the institution when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) the institution cannot supply a clinically equivalent alternative for the patient, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating cardiologist or lipidologist. ASCVD / HeFH documentation, statin-history confirmation, lipid-panel history, and clinical rationale (including formulary-gap note if applicable).
- Baseline assessment. Full lipid panel, hepatic and renal function, injection-technique training plan.
- KMOH named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, dosing schedule, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Repatha from authorised distribution under DSCSA.
- Cold-chain shipment. Repatha requires refrigerated handling; shipment follows validated cold-chain protocols with temperature logging.
- Arrival and dispensing. The hospital pharmacy releases the auto-injectors after clinic-based training.
What documentation your physician needs
- Clinical rationale letter (indication, statin history, Repatha as indicated therapy, formulary-gap note where relevant)
- Verification of Kuwait medical license (SCFHS)
- Lipid-panel history documenting LDL-C above goal
- Planned dosing schedule (every 2 weeks or monthly) and follow-up LDL-C cadence
Reserve Meds provides a physician documentation kit bundling templates KMOH reviewers expect for cardiology named-patient imports, including the formulary-gap clinical-rationale language.
Costs and timing
Repatha's US cash-pay drug-only reference cost sits in an indicative 2026 annual range of roughly USD 6,000-7,000. International logistics, KMOH documentation handling, cold-chain shipment, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.
Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete KMOH application is submitted.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and KMOH review.
- Logistics. Validated cold-chain shipment to your prescribing hospital.
- Concierge case lead. A named point of contact coordinating the every-2-week or monthly refill cadence.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating cardiologist.
Frequently asked
My hospital already stocks Repatha, do I need this pathway? No, if your hospital reliably stocks and dispenses Repatha for your indication, use the local pathway. Reserve Meds steps in only where there is a documented formulary or supply gap.
How does Repatha compare with Praluent or Leqvio? Repatha and Praluent are PCSK9 monoclonal antibodies dosed every 2-4 weeks; Leqvio is a PCSK9-targeting siRNA dosed every 6 months after loading. Your cardiologist selects based on adherence profile, dosing convenience, and payer considerations.
Can I self-inject at home? Yes, after clinic-based training on the auto-injector or prefilled syringe, consistent with FDA labeling.
Will insurance cover this? Cash-pay is the default. Some Kuwait private insurers consider case by case; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Reserve Meds AI Clinical and Regulatory Review (see /trust). Last medically reviewed: 2026-04-23.
Frequently asked questions
How can I get Repatha in Kuwait if it is not approved or available there?
Reserve Meds coordinates US-sourced Repatha for patients in Kuwait through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Kuwait and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Repatha in Kuwait through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Repatha. Eligibility and paperwork depend on the regulator in Kuwait, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Repatha in Kuwait through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Repatha to a patient in Kuwait?
Reserve Meds sources Repatha from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy in Kuwait, with appropriate handling for the product.
How long does it take, and what does Repatha in Kuwait cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Repatha in Kuwait?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.